Accepted for/Published in: Interactive Journal of Medical Research
Date Submitted: May 23, 2022
Date Accepted: Jul 28, 2022
Comparative Efficacy of Ranolazine versus Allopurinol for Eligible Symptomatic Patients with the History of Angioplasty
ABSTRACT
Background:
Recurrent angina in symptomatic patients who underwent angioplasty is a common problem that many cardiologists face on a daily basis.
Objective:
This study was aimed to compare the anti-anginal efficacy of Ranolazine versus Allopurinol for eligible symptomatic patients with the history of angioplasty.
Methods:
A total of 62 eligible symptomatic patients with the history of angioplasty were randomly allocated to 2 groups. For group A, Allopurinol 300 mg, twice daily was administered and for group B, Ranolazine 1000 mg, daily was administered for 4 weeks. An initial screening visit was done for all the participants. In this visit, patients' medical history was recorded; Physical examination, electrocardiography, blood pressure and heart rate measurements were done. Also, a blood test was carried out for the participants. In addition, exercise test was performed for all the patients. At the end of the medication period, participants were re-visited and the tests were done twice. All the required data was gathered in a researcher-made form and analyzed using SPSS22. The study was approved by a formal ethics committee.
Results:
The mean age of participants of groups (A and B) was 57.36±8.36 and 60.27±9.17, respectively. 34 patients (59%) were male and 28 patients (41%) were female. Creatinine; FBS; CRP; NT-pro BNP; Uric Acid; WBC and HB levels of participants were not significantly different between groups (P> 0.05). Booth Allopurinol and Ranolazine increased the total exercise time and decreased the ST depression of patients. Also, they improved the chest pain severity and Duke treadmill score of participants. At the same time, Ranolazine had a statistically greater effect on ST depression reduction (2.64±0.74 vs. 1.57±0.49) while Allopurinol showed better efficacy reducing chest pain severity (1.86±0.37 vs. 0.59±0.21) and Duke treadmill score (-14.77±3.65 vs. -6.88±1.93).
Conclusions:
The anti-anginal efficacy of Alloporinul and Ranolazine was approved but with different effects on the ST depression; chest pain severity and Duke treadmill score.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.